Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- L-seryl-L-prolyl-L-lysyl-L-methionyl-L-valyl-L-glutaminylglycyl-L-serylglycyl-L-cysteinyl-L-phenylalanylglycyl-L-arginyl-L-lysyl-L-methionyl-L-?-aspartyl-L-arginyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-lysyl-L-valyl-L-leucyl-L-arginyl-L-arginyl-L-histidine, cyclic (10?26)-disulfide, trifluoroacetate salt
- Correlated keywords
- 114471-18-0 132194-29-7 BNP32 nesiritide NPR-1 2 3 PGF-2? NPR1GCA GCA HEK-293 124584-08-3
- Product Overview:
Brain natriuretic peptide (BNP) (1-32) is an endogenous peptide that has cardiovascular functions and belongs to the family of natriuretic peptides, which includes atrial natriuretic peptide (ANP; Item Nos. 24276 | 24539 | 24540) and C-type natriuretic peptide (CNP; Item No. 24401).{36488,39460} It is an agonist of natriuretic peptide receptors (NPRs) 1 and 3 with Kd values of 7.3 and 13 pM, respectively, for human chimeric extracellular receptors fused to the constant domain of IgG.{39460} It also binds to human recombinant NPR1, also known as guanylyl cyclase-A (GC-A), and NPR3 with IC50 values of 8 and 2.6 nM, respectively, in radioligand binding assays.{36489} It is selective for NPR1/GC-A and NPR3 over NPR2/GC-B (Kd = 30,000 pM). BNP (1-32) activates NPR1/GC-A and increases cGMP levels with an EC50 value of 27 nM in HEK293 cells expressing the human receptor and stimulates cGMP accumulation in cultured bovine aortic endothelial and aortic smooth muscle cells (EC50s = 9 and 17 nM, respectively).{36489,36490} It also relaxes contractions induced by prostaglandin F2? (PGF2?) in isolated porcine coronary artery and rat aortic strips (IC50s = 0.02 and 12.1 nM, respectively).{36491} In rats, BNP (1-32) (10 nmol/kg) increases mean urine flow and the sodium excretion rate. Formulations containing BNP (1-32) have been used in the treatment of acutely decompensated congestive heart failure.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.